睿知中国疾病研究地图
候选清单0

正在招募肝细胞癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of GV20-0251 in Advanced or Refractory Solid Tumors

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由四川大学华西医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方四川大学华西医院West China Hospital成都医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07106827,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Previously treated, histologically-confirmed advanced solid malignancy with progressive disease requiring therapy (Refractory or intolerant to standard therapies, must have received the standard of care therapy)

    入选标准第 4 条

  3. Prior anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of GV20-0251 on Cycle 1 Day 1 (C1D1), with the exceptions.

    排除标准第 12 条

    Any history of an immune-related ≥ Grade 3 AE attributed to prior cancer immunotherapy

    排除标准第 16 条

  4. ECOG performance status of 0 or 1 before C1D1

    入选标准第 5 条

  5. Known human immunodeficiency virus (HIV) infection, known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection, unless meeting the specific conditions.

    排除标准第 6 条

  6. Pregnant or nursing women

    排除标准第 10 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07106827,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Before conducting any study-specific procedures, voluntarily sign an informed consent form.
  2. Be able and willing to participate throughout the entire study period and comply with study procedures.
  3. participants ≥18 years of age
  4. Previously treated, histologically-confirmed advanced solid malignancy with progressive disease requiring therapy (Refractory or intolerant to standard therapies, must have received the standard of care therapy)
  5. ECOG performance status of 0 or 1 before C1D1
  6. Disease-free of active second/secondary or prior malignancies for ≥ 2 years Laboratory test results within the required parameters
  7. Women of childbearing potential (WOCBP) and men must agree to use adequate contraception

排除标准:Exclusion Criteria:

  1. Participants with acute leukemia or CLL
  2. Participant with heart disease, myocardial infarction within the past 6 months, or unstable arrhythmia
  3. Fridericia-corrected QT interval (QTcF) > 470 msec, or the presence of congenital long QT syndrome, or a history of clinically significant electrocardiogram (ECG) abnormalities (including pericarditis) that, in the investigator's judgment, may affect the subject's safety.
  4. Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy within 7 days of Cycle 1 Day 1 (C1D1)
  5. Participant has active autoimmune disease or other medical conditions requiring chronic systemic steroid or immunosuppressive therapy
  6. Known human immunodeficiency virus (HIV) infection, known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection, unless meeting the specific conditions.
  7. History of major organ transplant and/or a bone marrow transplant
  8. Symptomatic central nervous system (CNS) malignancy or metastasis
  9. Serious nonmalignant disease
  10. Pregnant or nursing women
  11. Major surgery within 28 days prior to the first dose of study medication
  12. Prior anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of GV20-0251 on Cycle 1 Day 1 (C1D1), with the exceptions.
  13. History of severe allergic reactions to biologic therapy, which in the investigator's judgment may increase the subject's risk.
  14. Radiation therapy for symptomatic lesions within 14 days prior to C1D1 dosing.
  15. Active substance abuse
  16. Any history of an immune-related ≥ Grade 3 AE attributed to prior cancer immunotherapy

引自 ClinicalTrials.gov, NCT07106827, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07106827,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07106827